Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
ZAMBON S.P.A. manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently has 2 pending office actions. These actions are distributed across 2 distinct examiners, indicating that each examiner is handling a separate matter.
The prosecution activity spans 2 distinct art units. Mina Haghighatian is the busiest examiner for the portfolio, with 1 pending office action. This means the remaining pending workload is handled by the other distinct examiner involved in the company's current filings.
The presence of 2 distinct art units suggests a broader technical range for the pending applications compared to single-unit portfolios. With 2 distinct examiners, the company must navigate different individual preferences. The 2 pending office actions represent the current active workload requiring attention from the legal team. This distribution across 2 art units and 2 examiners highlights the variety of the company's current patent efforts.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGHIGHATIAN, MINA | 1 | 46.1% | +39.3% |
| ABBAS, ABDULRAHMAN MUSTAFA | 1 | 52.4% | +34.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18265463 | METHOD FOR MANUFACTURING AN INHALABLE POWDER COMPRISING VORICONAZOLE | HAGHIGHATIAN, MINA | 29d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18265463 | METHOD FOR MANUFACTURING AN INHALABLE POWDER COMPRISING VORICONAZOLE | HAGHIGHATIAN, MINA | 29d |
| 17778007 | PROCESS FOR THE PREPARATION OF DISPERSIONS COMPRISING INHALABLE IMMUNOSUPPRESSIVE ACTIVE INGREDIENTS | ABBAS, ABDULRAHMAN MUSTAFA | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18265463 | METHOD FOR MANUFACTURING AN INHALABLE POWDER COMPRISING VORICONAZOLE | HAGHIGHATIAN, MINA | 1616 | §103§112 | Final Rejection | 29d | Pending | Jun 06, 2023 |
| 17778007 | PROCESS FOR THE PREPARATION OF DISPERSIONS COMPRISING INHALABLE IMMUNOSUPPRESSIVE ACTIVE INGREDIENTS | ABBAS, ABDULRAHMAN MUSTAFA | 1612 | §103DP | Non-Final OA | — | Pending | May 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial